Your browser is no longer supported. Please, upgrade your browser.
Enanta Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.16 Insider Own3.50% Shs Outstand20.20M Perf Week11.14%
Market Cap1.58B Forward P/E- EPS next Y-5.06 Insider Trans-3.09% Shs Float17.87M Perf Month41.30%
Income-83.70M PEG- EPS next Q-0.84 Inst Own95.00% Short Float8.90% Perf Quarter87.31%
Sales97.10M P/S16.24 EPS this Y-182.00% Inst Trans0.55% Short Ratio10.66 Perf Half Y55.83%
Book/sh20.68 P/B3.87 EPS next Y-35.60% ROA-17.80% Target Price70.70 Perf Year77.78%
Cash/sh13.03 P/C6.14 EPS next 5Y- ROE-19.00% 52W Range40.32 - 80.35 Perf YTD90.07%
Dividend- P/FCF- EPS past 5Y-19.60% ROI-9.40% 52W High2.87% Beta0.50
Dividend %- Quick Ratio11.20 Sales past 5Y-5.30% Gross Margin- 52W Low105.01% ATR2.74
Employees141 Current Ratio11.20 Sales Q/Q15.50% Oper. Margin-98.60% RSI (14)82.54 Volatility4.41% 4.27%
OptionableYes Debt/Eq0.00 EPS Q/Q-66.90% Profit Margin-86.20% Rel Volume1.41 Prev Close80.02
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume149.09K Price82.66
Recom2.60 SMA2019.82% SMA5035.51% SMA20060.53% Volume99,712 Change3.30%
Oct-07-21Initiated Jefferies Buy $95
Sep-09-21Initiated SVB Leerink Mkt Perform $55
Jan-29-21Upgrade JP Morgan Underweight → Neutral $55
Nov-24-20Initiated Evercore ISI Underperform $30
Aug-28-20Resumed ROTH Capital Buy $104
Aug-26-20Initiated Piper Sandler Overweight $87
Jul-27-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $70
Mar-17-20Upgrade Robert W. Baird Neutral → Outperform $60
Nov-22-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-19Downgrade JP Morgan Neutral → Underweight $86 → $57
May-24-19Initiated Wolfe Research Outperform $117
Apr-23-19Upgrade Berenberg Hold → Buy $80 → $120
Dec-13-18Initiated Berenberg Hold $80
Jun-06-18Initiated ROTH Capital Buy $133
Feb-08-18Downgrade JP Morgan Overweight → Neutral
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17Reiterated RBC Capital Mkts Outperform $54 → $58
Sep-15-17Initiated RBC Capital Mkts Outperform $54
Jul-11-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-19-21 10:42AM  
Oct-14-21 11:21AM  
Oct-08-21 08:21AM  
Oct-06-21 08:16AM  
Oct-05-21 07:00AM  
Oct-04-21 04:29PM  
Oct-01-21 07:00AM  
Sep-28-21 07:00AM  
Sep-07-21 07:00AM  
Aug-23-21 07:00AM  
Aug-16-21 07:00AM  
Aug-13-21 02:12AM  
Aug-06-21 12:01AM  
Aug-05-21 06:05PM  
Jul-29-21 07:00AM  
Jul-27-21 03:03PM  
Jul-14-21 05:30PM  
Jun-23-21 02:01AM  
Jun-22-21 04:01PM  
Jun-10-21 07:00AM  
Jun-03-21 07:00AM  
May-11-21 07:00AM  
May-07-21 09:58AM  
May-06-21 05:45PM  
Apr-29-21 07:00AM  
Apr-28-21 12:33PM  
Mar-02-21 07:01AM  
Feb-18-21 04:02PM  
Feb-08-21 11:00PM  
Feb-05-21 10:09AM  
Feb-01-21 04:02PM  
Jan-28-21 12:32PM  
Jan-26-21 07:00AM  
Jan-08-21 07:01AM  
Jan-05-21 07:01AM  
Dec-19-20 10:40PM  
Dec-08-20 07:01AM  
Nov-25-20 12:10AM  
Nov-23-20 10:00PM  
Nov-20-20 10:03AM  
Nov-18-20 07:02AM  
Nov-16-20 07:02AM  
Nov-12-20 12:30PM  
Oct-27-20 09:54AM  
Oct-12-20 01:27PM  
Sep-28-20 07:00AM  
Sep-14-20 07:00AM  
Sep-03-20 07:01AM  
Aug-28-20 06:15AM  
Aug-26-20 09:42AM  
Aug-20-20 07:00AM  
Aug-07-20 09:28AM  
Aug-05-20 01:31AM  
Aug-04-20 06:35PM  
Aug-03-20 07:02AM  
Jul-28-20 12:32PM  
Jul-17-20 01:41PM  
Jul-09-20 07:01AM  
Jun-29-20 07:00AM  
Jun-23-20 12:23PM  
Jun-11-20 07:02AM  
Jun-04-20 10:20PM  
May-23-20 09:58AM  
May-14-20 08:53AM  
May-12-20 07:30AM  
May-09-20 09:43PM  
May-07-20 12:01AM  
May-06-20 06:45PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-17-20 10:19AM  
Mar-26-20 04:05PM  
Mar-13-20 07:00AM  
Mar-06-20 07:05AM  
Mar-04-20 08:09AM  
Feb-12-20 12:18AM  
Feb-06-20 05:15PM  
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Adda NathalieSr. VP & Chief Medical OfficerOct 11Option Exercise43.464,047175,88330,991Oct 13 06:39 PM
Adda NathalieSr. VP & Chief Medical OfficerOct 11Sale70.344,047284,68526,944Oct 13 06:39 PM
Adda NathalieSr. VP & Chief Medical OfficerOct 08Option Exercise43.4613,453584,66740,397Oct 13 06:39 PM
Adda NathalieSr. VP & Chief Medical OfficerOct 08Sale70.0913,453942,93426,944Oct 13 06:39 PM
Luly Jay R.President and CEOSep 15Sale59.064,516266,698676,972Sep 17 05:17 PM
Or Yat SunSr. VP & CSOJan 26Option Exercise12.6813,693173,576330,918Jan 28 05:41 PM
MELLETT PAUL JTreasurer and CFOJan 08Sale45.586,000273,46361,759Jan 08 08:57 PM
Gardiner Nathaniel S.Sr. VP & General CounselDec 03Option Exercise30.001,66750,01038,538Dec 07 05:38 PM
MELLETT PAUL JTreasurer and CFONov 11Option Exercise2.543,4808,84946,304Nov 12 04:12 PM